Detection of Amyloid Plaques Targeted by Bifunctional USPIO in Alzheimer’s Disease Transgenic Mice Using Magnetic Resonance Microimaging
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Amyloid plaques are a key pathological hallmark of Alzheimer's disease (AD). The detection of amyloid plaques in the brain is important for the diagnosis of AD, as well as for following potential amyloid targeting therapeutic interventions. Our group has developed several contrast agents to detect amyloid plaques in vivo using magnetic resonance microimaging (µMRI) in AD transgenic mice, where we used mannitol to enhance blood brain barrier (BBB) permeability. In the present study, we used bifunctional ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles, chemically coupled with Aβ1-42 peptide to image amyloid plaque deposition in the mouse brain. We coupled the nanoparticles to polyethylene glycol (PEG) in order to improve BBB permeability. These USPIO-PEG-Aβ1-42 nanoparticles were injected intravenously in AD model transgenic mice followed by initial in vivo and subsequent ex vivo μMRI. A 3D gradient multi-echo sequence was used for imaging with a 100 µm isotropic resolution. The amyloid plaques detected by T2*-weighted μMRI were confirmed with matched histological sections. The region of interest-based quantitative measurement of T2* values obtained from the in vivo μMRI showed contrast injected AD Tg mice had significantly reduced T2* values compared to wild-type mice. In addition, the ex vivo scans were examined with voxel-based analysis (VBA) using statistical parametric mapping (SPM) for comparison of USPIO-PEG-Aβ1-42 injected AD transgenic and USPIO alone injected AD transgenic mice. The regional differences seen by VBA in the USPIO-PEG-Aβ1-42 injected AD transgenic correlated with the amyloid plaque distribution histologically. Our results indicate that USPIO-PEG-Aβ1-42 can be used for amyloid plaque detection in vivo by intravenous injection without the need to co-inject an agent which increases permeability of the BBB. This technique could aid the development of novel amyloid targeting drugs by allowing therapeutic effects to be followed longitudinally in model AD mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some studies have co-injected intravenously with mannitol or polyethylene glycol to transiently open the BBB to amplify the abilities of USPIO coupled with Aβ (1-42) to detect Aβ in AD model mice.[22][23]”
From Amyloid Plaque Imaging with a Targeted MRI Contrast Agent in a Transgenic Mouse Model of Alzheimer’s Disease (2022) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386 · cited 2×
“This transgenic line is based on the overexpression of both amyloid precursor protein mutations (APPK670N/M671L) and mutant presenilin-1 (PS1M146L) [36].”
BackgroundImaging β-amyloid burden in aging and dementia
Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104
Weissleder, R., Elizondo, G., Wittenberg, J., Rabito, C. A., Bengele, H. H., & Josephson, L. (1990) · Radiology · doi:10.1148/radiology.175.2.2326474 · Cited by 1,028 · cited 1×
“USPIO are known to have much longer plasma K life of 24–36hr in humans [28,29] and ,2 hours in mice [30].”
Background2012 Alzheimer's disease facts and figures Alzheimer's Association ∗
Thies, W., & Bleiler, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.02.001 · Cited by 982
In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity
Pike, C. J., Walencewicz, A. J., Glabe, C. G., & Cotman, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)91553-d · Cited by 828 · cited 6×
“Another cause of potential concern with USPIO-PEG-Ab1-42 is the known toxicity of Ab1-42 at micromolar concentrations [39].”
BackgroundMethodInfluentialNeuropathology of Alzheimer's Disease
Perl, D. P. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20157 · Cited by 825
Computational anatomy with the SPM software
Ashburner, J. (2009) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2009.01.006 · Cited by 564 · cited 1×
“The steps involved in processing data were similar to that of human data processing and as we published previously [27,45].”
ResultWeissleder, R., Elizondo, G., Wittenberg, J., Lee, A. S., Josephson, L., & Brady, T. J. (1990) · Radiology · doi:10.1148/radiology.175.2.2326475 · Cited by 492 · cited 1×
“The plasma 1/2 life of USPIO has previously been shown to be , 2 hr in mice [52], while in humans the plasma K life is 24-36hr [28,29].”
BackgroundLong-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo, P., Gouritin, B., Chacun, H., Desmaële, D., D'Angelo, J., Noel, J.-P., Georgin, D., Fattal, E., Andreux, J. P., & Couvreur, P. (2001) · Pharmaceutical Research · doi:10.1023/a:1010931127745 · Cited by 443 · cited 3×
“However, this technique still requires femoral co-injection of mannitol for CNS imaging as USPIO do not cross the intact BBB.”
Background
Research works printed but not linked: 1
- M Sadowski, 2006, Blocking the apolipoproteinE/Amyloid β interaction reduces the parenchymal and vascular amyloid-β deposition and prevents memory deficit in AD transgenic mice, Proc Natl Acad Sci (USA), 103(49), 18787
Cited by
Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers
Wahsner, J., Gale, E. M., Rodríguez-Rodríguez, A., & Caravan, P. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00363 · Cited by 1,603
Cheng, K. K., Chan, P. S., Fan, S., Kwan, S. M., Yeung, K. L., Wáng, Y.-X. J., Chow, A. H. L., Wu, E. X., & Baum, L. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.005 · Cited by 293
“The authors have introduced a new nano formulation using a less toxic fragment of Ab peptide [23] and co-linking with polyethylene glycol (PEG) to replace co-injection of mannitol [24].”
BackgroundMethodResultMagnetic iron oxide nanoparticles for brain imaging and drug delivery
Qiao, R., Fu, C., Forgham, H., Javed, I., Huang, X., Zhu, J., Whittaker, A. K., & Davis, T. P. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114822 · Cited by 245
Wallyn, J., Anton, N., & Vandamme, T. F. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110601 · Cited by 207
“In this way, magnetic NPs have already been involved into various biomedical applications including dental applications [15], and illnesses local treatment like neurological diseases [16] and cardiovascular diseases [13].”
BackgroundNiu, X., Chen, J., & Gao, J. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2018.09.005 · Cited by 190
“[82] Wadghiri YZ , Li J , Wang J , et al.”
BackgroundRahman, M. M., Islam, M. R., Akash, S., Harun-Or-Rashid, M., Ray, T. K., Rahaman, M. S., Islam, M., Anika, F., Hosain, M. K., Aovi, F. I., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113305 · Cited by 173
RetractedHu, B., Dai, F., Fan, Z., Ma, G., Tang, Q., & Zhang, X. (2015) · Advanced Materials · doi:10.1002/adma.201502227 · Cited by 155
Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview
Bilal, M., Barani, M., Sabir, F., Rahdar, A., & Kyzas, G. Z. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100251 · Cited by 126
Nano- and neurotoxicology: An emerging discipline
Bencsik, A. A., Lestaevel, P., & Canu, I. G. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.003 · Cited by 127
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases
Gendelman, H. E., Anantharam, V., Bronich, T., Ghaisas, S., Jin, H., Kanthasamy, A. G., Liu, X., McMillan, J., Mosley, R. L., Narasimhan, B., et al. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2014.12.014 · Cited by 117
“Kuo and Su demonstrated that stavudine, delavirdine and saquinavir encapsulated in SLNs more readily passed across an artificial BBB compared to unencapsulated drugs.101 In other in vitro studies, Kuo and Ko used the insulin-like peptidomimetic monoclonal antibody, 83-14 MAb, as a targeting moiety to improve penetrati…”
BackgroundInfluentialLuo, S., Ma, C., Zhu, M.-Q., Ju, W.-N., Yang, Y., & Wang, X. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00021 · Cited by 109
Kogan, M. J., Aguirre, M. V., Morales-Zavala, F., Toledo, E. G., Guerrero, S., Giralt, E., & Araya, E. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s82310 · Cited by 123
“On the other hand, the conjugation of ultrasmall superparamagnetic iron oxide (USPIO) to Aβ1-42 allows the detection of amyloid plaques in vivo using magnetic resonance microimaging (mMRI) after intravenous femoral injection in a Tg mice model of Alzheimer’s disease.(120) The amyloid plaques were detected by T2*-weigh…”
MethodTargeted Drug Delivery to the Brain Using Magnetic Nanoparticles
Thomsen, L. B., Thomsen, M. S., & Moos, T. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.56 · Cited by 95
Circulating microRNAs in Huntington’s disease: Emerging mediators in metabolic impairment
Díez‐Planelles, C., Sánchez-Lozano, P., Crespo, M. C., Gil‐Zamorano, J., Ribacoba, R., González, N., Suárez, E., Martínez‐Descals, A., Martínez‐Camblor, P., Álvarez, V., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.005 · Cited by 99
Metal-based imaging agents: progress towards interrogating neurodegenerative disease
Sedgwick, A. C., Brewster, J. T., Harvey, P., Iovan, D. A., Smith, G. S. T., He, X., Tian, H., Sessler, J. L., & James, T. D. (2020) · Chemical Society Reviews · doi:10.1039/c8cs00986d · Cited by 89
Hikishima, K., Komaki, Y., Seki, F., Ohnishi, Y., Okano, H. J., & Okano, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-00148-1 · Cited by 77
GRE T2 * -Weighted MRI: Principles and Clinical Applications
Tang, M. Y., Chen, T. W., Zhang, X. M., & Huang, X. (2014) · BioMed Research International · doi:10.1155/2014/312142 · Cited by 82
“Its appearance on the GRE T2WI is a local signal loss [21, 22].”
Metal Nanoparticles as Targeted Carriers Circumventing the Blood–Brain Barrier
Sintov, A. C., Velasco-Aguirre, C., Gallardo-Toledo, E., Araya, E., & Kogan, M. J. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.06.007 · Cited by 71
Therapeutic approaches of magnetic nanoparticles for the central nervous system
Dilnawaz, F., & Sahoo, S. K. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.06.008 · Cited by 78
Neurobehavioural Toxicity of Iron Oxide Nanoparticles in Mice
Vasanth, D., Manickam, V., & Perumal, E. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9721-1 · Cited by 68
Fernández, T., Martínez-Serrano, A., Cussó, L., Desco, M., & Ramos-Gómez, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00260 · Cited by 65
Abdullah, S. A., Najm, L., Ladouceur, L., Ebrahimi, F., Shakeri, A., Al‐Jabouri, N., Didar, T. F., & Dellinger, K. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202302673 · Cited by 68
Bort, G., Catoen, S., Borderies, H., Kebsi, A., Ballet, S., Louin, G., Port, M., & Ferroud, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.016 · Cited by 65
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Self-citationHill, L. K., Frezzo, J. A., Katyal, P., Hoang, D. M., Youss, Z. B., Xu, C., Xie, X., Delgado-Fukushima, E., Wadghiri, Y. Z., & Montclare, J. K. (2019) · ACS Nano · doi:10.1021/acsnano.8b07481 · Cited by 61
Self-citationNasr, S. H., Kouyoumdjian, H., Mallett, C. L., Ramadan, S., Zhu, D. C., Shapiro, E. M., & Huang, X. (2017) · Small · doi:10.1002/smll.201701828 · Cited by 57
Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review
Pansieri, J., Gerstenmayer, M., Lux, F., Mériaux, S., Tillement, O., Forge, V., Larrat, B., & Marquette, C. (2018) · Nanomaterials · doi:10.3390/nano8090740 · Cited by 52
“As an example, using USPIO-PEG-Aβ1–42 [92], authors reported hypo-signals similar to a compound targeting amyloid in wild-type (WT) mice, emphasizing the difficulty in distinguishing marked amyloid plaques from blood vessels on T2* images.”
BackgroundEntorhinal cortical defects in Tg2576 mice are present as early as 2–4 months of age
Duffy, Á. M., Morales-Corraliza, J., Bermudez-Hernandez, K. M., Schaner, M. J., Magagna-Poveda, A., Mathews, P. M., & Scharfman, H. E. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.001 · Cited by 52
Nanomedicines in the Management of Alzheimer’s Disease: Current View and Future Prospects
Chopra, H., Bibi, S., Singh, I., Kamal, M. A., Islam, F., Alhumaydhi, F. A., Emran, T. B., & Cavalu, S. D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.879114 · Cited by 49
Nanotechnologies for the study of the central nervous system
Ajetunmobi, A., Prina‐Mello, A., Volkov, Y., Corvin, A. P., & Tropea, D. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.09.004 · Cited by 47
Nanoneuromedicine for management of neurodegenerative disorder
Dwivedi, N., Shah, J., Mishra, V. K., Tambuwala, M. M., & Kesharwani, P. (2018) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2018.12.021 · Cited by 46
Stimuli-controllable iron oxide nanoparticle assemblies: Design, manipulation and bio-applications
Low, L. E., Lim, H. P., Ong, Y. S., Siva, S. P., Sia, C. S., Goh, B. H., Chan, E., & Tey, B. T. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.024 · Cited by 47
The detection of β-amyloid plaques in an Alzheimer's disease rat model with DDNP-SPIO
Zhang, D., Fa, H., Zhou, J., Li, S., Diao, X.-W., & Yin, W. H. (2014) · Clinical Radiology · doi:10.1016/j.crad.2014.09.019 · Cited by 46
Margel, S., Skaat, H., Corem‐Salkmon, E., Grinberg, I., Last, D., Goez, D., & Mardor, Y. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s52833 · Cited by 58
Azria, D., Blanquer, S., Verdier, J.-M., & Belamie, E. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01599b · Cited by 41
A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging
Tanifum, E. A., Ghaghada, K., Vollert, C., Head, E., Eriksen, J. L., & Annapragada, A. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151124 · Cited by 44
Salerno, M., & Porqueras, D. S. D. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.04.018 · Cited by 45
A Promising Approach: Magnetic Nanosystems for Alzheimer’s Disease Theranostics
Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092316 · Cited by 40
“Later, the same authors reported the functionalization of poly(ethylene) glycol (PEG)-coated ultrasmall SPIONs (USPIONs) with Aβ1–42 peptides [66].”
BackgroundNanoparticles as Contrast Agents for The Diagnosis of Alzheimer’s Disease: A Systematic Review
Ulanova, M., Poljak, A., Wen, W. X., Bongers, A., Gloag, L., Gooding, J. J., Tilley, R. D., Sachdev, P. S., & Braidy, N. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0316 · Cited by 42
Diagnostic and Therapeutic Uses of Nanomaterials in the Brain
Garbayo, E., de Mendoza, A. E., & Blanco‐Prieto, M. J. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140815124246 · Cited by 40
“24 The use of iron oxide NP as MRI contrast agents has been extensively investigated The most frequent iron oxide NP conjugated to Aβ peptide for amyloid plaque detection are monocrystalline iron oxide NP (MIONs) [151], small SPIONP [159] and USPIONP [152].”
BackgroundInfluentialEnabling biodegradable functional biomaterials for the management of neurological disorders
Shan, D., Ma, C., & Yang, J. Y. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.06.004 · Cited by 39
Huang, R., Zhou, X., Chen, G., Su, L., Liu, Z., Zhou, P., Weng, J., & Min, Y. (2022) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1800 · Cited by 41
Alzheimer’s disease: review of current nanotechnological therapeutic strategies
Baranowska‐Wójcik, E., & Szwajgier, D. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1719069 · Cited by 38
“[58] used bifunctional nanoparticles of”
Dudeffant, C., Vandesquille, M., Herbert, K., Garin, C. M., Alves, S., Blanchard, V., Comoy, E. E., Petit, F., & Dhenain, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-05285-1 · Cited by 34
Magnetic Resonance Imaging in Animal Models of Alzheimer’s Disease Amyloidosis
Ni, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312768 · Cited by 37
“B APP/PS1 mice [40] T1w SE, ADx-001 APP/PS1 mice [38] T2*w, anti-AβPP SPIONs APP/PS1 mice [42] T2*w, IgG4.”
Tafoya, M., Madi, S., & Sillerud, L. O. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25563 · Cited by 32
“Our novel FePt nanoparticles were successfully used to detect active microglia using much the same MR approach as with Ab detection by the SPIONs.”
BackgroundMethodInfluentialNanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Nanomedicine-based immunotherapy for Alzheimer's disease
Hoque, M., Samanta, A., Alam, S. S. M., Zughaibi, T. A., Kamal, M. A., & Tabrez, S. S. M. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104973 · Cited by 34
High-resolution Imaging of Myeloperoxidase Activity Sensors in Human Cerebrovascular Disease
Wadghiri, Y. Z., Hoang, D. M., Leporati, A. M., Gounis, M. J., Rodríguez‐Rodríguez, A., Mazzanti, M. L., Weaver, J. P., Wakhloo, A. K., Caravan, P. D., & Bogdanov, A. A., Jr. (2018) · Scientific Reports · doi:10.1038/s41598-018-25804-y · Cited by 30
Self-citationCerebral Vascular Leak in a Mouse Model of Amyloid Neuropathology
Tanifum, E. A., Starosolski, Z. A., Fowler, S. W., Jankowsky, J. L., & Annapragada, A. V. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.125 · Cited by 28
Martins, A. F., Oliveira, A. C., Morfin, J., Laurents, D. V., Tóth, É., & Geraldes, C. F. G. C. (2015) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-015-1316-9 · Cited by 28
Bigot, C., Vanhoutte, G., Verhoye, M., & der Linden, A. V. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.10.056 · Cited by 27
“Wadghiri et al. (2013) recently succeeded to detect amyloid plaques using targeted liposomes without additional agents.”
BackgroundMagnetic Nanoparticles as In Vivo Tracers for Alzheimer’s Disease
Sharma, B., & Pervushin, K. V. (2020) · Magnetochemistry · doi:10.3390/magnetochemistry6010013 · Cited by 26
“reported the use of Polyethylene glycol (PEG) for coating iron oxide nanoparticles, which not only showed a decrease in the effects of immunotoxicity but also improved the BBB permeability [11].”
BackgroundDelbreil, P., Rabanel, J., Banquy, X., & Brambilla, D. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114397 · Cited by 28
Gadolinium-complexed Aβ-binding contrast agents for MRI diagnosis of Alzheimer's Disease
Matharu, B., Spencer, N., Howe, F. A., & Austen, B. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.07.001 · Cited by 24
“…iron oxide (USPIO) nanoparticles enhanced the T2*weighted MRI in vivo in AD transgenic mice, either with iv co-injection ofmannitol to open theblood–brain barrier, or by the attachment of polyethylene glycol to the nanoparticles, to improve BBB permeability (Wadghiri et al., 2013).”
Fernández, T., & Ramos, M. (2019) · Nanoscale Research Letters · doi:10.1186/s11671-019-2863-8 · Cited by 22
Shin, S. S., & Pelled, G. (2017) · Frontiers in Neural Circuits · doi:10.3389/fncir.2017.00015 · Cited by 20
“Magnetic imaging research in neurological diseases has progressed in various areas: detecting specific molecular target (Wadghiri et al., 2013), microstructural injury (Shin et al., 2014), as well as alterations in functional correlation of different regions of the brain (Boly et al., 2009; Iraji…”
BackgroundRoss, A. M., Nulty, D. M., O’Dwyer, C., Grabrucker, A. M., Cronin, P., & Mulvihill, J. J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.022 · Cited by 19
Reduction of Amyloid-β Deposition and Attenuation of Memory Deficits by Tolfenamic Acid
Subaiea, G. M., Ahmed, A. H., Adwan, L. I., & Zawia, N. H. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132726 · Cited by 19
“Using ImageJ software for plaque quantification has been documented and validated in several publications [24–26].”
MethodMouse models of neurodegenerative disease: preclinical imaging and neurovascular component
Albanese, S., Greco, A., Auletta, L., & Mancini, M. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9770-3 · Cited by 16
Abi‐Ghanem, C., Jonnalagadda, D., Chun, J. J. M., Kihara, Y., & Ranscht, B. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.908401 · Cited by 16
“, 2020), and detection of amyloid plaques in Alzheimer’s models (Wadghiri et al., 2013).”
BackgroundAndré, S., Ansciaux, E., Saidi, E., Larbanoix, L., Stanicki, D., Nonclercq, D., Elst, L. V., Laurent, S., Müller, R. N., & Burtéa, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170563 · Cited by 16
“To bind AP, MRI CA were linked to A 42 [12] 89 or a fragment of A [13] using the intrinsic property 90 of A to self-aggregate.”
MethodMetal complexes for multimodal imaging of misfolded protein-related diseases
Lacerda, S., Morfin, J., Geraldes, C. F. G. C., & Tóth, É. (2017) · Dalton Transactions · doi:10.1039/c7dt02371e · Cited by 15
Razavi, R., khajouei, G., Divsalar, F., Dawi, E. A., & Amiri, M. (2025) · Reviews in the Neurosciences · doi:10.1515/revneuro-2024-0086 · Cited by 16
Nanoparticles for Diagnosis and/or Treatment of Alzheimer's Disease
Antimisiaris, S. G., Mourtas, S., Markoutsa, E., Σκούρας, Α., & Παπαδιά, Κ. (2014) · Wiley eBooks · doi:10.1002/9781118774205.ch4 · Cited by 12
Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease
Liu, X., Yuan, M., Li, L., Zhang, J., Huang, X. P., Du, J., Tu, Z., & Wu, H. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221216114912 · Cited by 11
Ulanova, M., Gloag, L., Bongers, A., Kim, C.-K., Duong, H. T. K., Kim, H. N., Gooding, J. J., Tilley, R. D., Biazik, J. M., Wen, W. X., et al. (2023) · Cells · doi:10.3390/cells12182279 · Cited by 11
In Vivo MRI of Amyloid Plaques in a Cholesterol-Fed Rabbit Model of Alzheimer’s Disease
Chen, Y., Lim, P. H., Rogers, K. A., Rutt, B. K., & Ronald, J. A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180207 · Cited by 10
“Subsequent studies have demonstrated non-invasive in vivo detection of A (cid:2) plaques in transgenic mouse models [43–50].”
Mouse brain magnetic resonance microscopy: Applications in A lzheimer disease
Lin, L., Fu, Z., Xu, X., & Wu, S. (2015) · Microscopy Research and Technique · doi:10.1002/jemt.22489 · Cited by 10
“Wadghiri et al. (2013) used bifunctional USPIO nanoparticles, coupled the nanoparticles to polyethylene glycol to improve BBB permeability and chemically coupled with Ab1-42 peptide to image amyloid plaque deposition.”
MethodKincses, Z. T., Király, A., Veréb, D., & Vécsei, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143195 · Cited by 11
“Nevertheless, with certain molecular modification it is possible to bypass the blood-brain barrier [177, 178], and further non-biologic functionalized nanoparticles are under development [179].”
Iron Oxide Magnetic Nanoparticles (NPs) Tailored for Biomedical Applications
Zoppellaro, G. (2020) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-030-39923-8_2 · Cited by 8
Microenvironment-tailored nanoassemblies for the diagnosis and therapy of neurodegenerative diseases
Low, L. E., Wang, Q., Chen, Y., Lin, P., Yang, S., Gong, L., Lee, J., Siva, S. P., Goh, B. H., Li, F., et al. (2021) · Nanoscale · doi:10.1039/d1nr02127c · Cited by 8
Nanobiosensors for early detection of neurodegenerative disease
Fazlali, P., Mahdian, A., Soheilifar, M. S., Amininasab, S. M., Shafiee, P., Wani, I. A., & AL-Mokaram, A. M. A. A. A. (2022) · Journal of Composites and Compounds · doi:10.52547/jcc.4.1.4 · Cited by 8
Molecular Design of Magnetic Resonance Imaging Agents Binding to Amyloid Deposits
Nikiforova, A. A., & Sedov, I. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311152 · Cited by 7
“[199] and in a number of later studies, β-amyloid peptides or their fragments and derivatives were conjugated with gadolinium complexes [200–202] or superparamagnetic iron oxide nanoparticles (SPIONs) [203,204].”
BackgroundNanotechnology-Mediated Nose-to-Brain Drug Delivery for Neurodegenerative Disorders
Pardeshi, C. V., Belgamwar, V. S., & Surana, S. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_6 · Cited by 8
Peptide-metal nanohybrids (PMN): Promising entities for combating neurological maladies
Kour, A., Panda, H. S., Singh, I. R., Kumar, A., & Panda, J. J. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.102954 · Cited by 7
Nanoparticle-Based Imaging Techniques in Neurological Disorders
Thangaleela, S., Wang, C., Revathi, S., Sivamaruthi, B. S., & Chaiyasut, C. (2025) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-80185-3_3 · Cited by 11
Nanotechnology at the Rescue of Neurodegenerative Diseases: Tools for Early Diagnostic
Rabanel, J., Perrotte, M., & Ramassamy, C. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_2 · Cited by 6
COB231 targets amyloid plaques in post‐mortem human brain tissue and in an Alzheimer mouse model
Garin, D., Virgone‐Carlotta, A., Gözel, B., Oukhatar, F., Perret, P., Batlle, D. M., Touret, M., Millet, P., Dubois‐Dauphin, M., Meyronet, D., et al. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.12951 · Cited by 7
Unveiling the theranostic potential of SPIONs in Alzheimer's disease management
Aminyavari, S., Afshari, A. R., Ahmadi, S. S., Kesharwani, P., Sanati, M., & Sahebkar, A. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.09.022 · Cited by 5
Valdora, F., Cutrona, G., Matis, S., Morabito, F., Massucco, C., Emionite, L., Boccardo, S., Basso, L., Recchia, A. G., Salvi, S., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.07.013 · Cited by 5
Mohapatra, S., Guerrero, A., Rahman, N., Zaman, K., Wu, J., Onyeagba, C., Hu, C., Pellegrini, M. A., Jayaram, V., Kitamura, S., et al. (2025) · Cells · doi:10.3390/cells14211703 · Cited by 5
“Similar to previous studies [31,32], we employed a high-throughput ex vivo MRI approach, enabling simultaneous scanning of multiple samples using extended overnight imaging time.”
Self-citationLerouge, F., Ong, E., Rositi, H., Mpambani, F., Berner, L.-P., Bolbos, R. I., Olivier, C., Peyrin, F., Apputukan, V. K., Monnereau, C., et al. (2022) · Nanomedicine · doi:10.2217/nnm-2022-0252 · Cited by 5
Experimental Models in Neurodegenerative Diseases
Korkmaz, Ü., & Kaya, M. (2019) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2019.0009 · Cited by 7
“Bu görüntülerde, AP ile komşu beyin dokusu arasındaki zemin/lezyon oranı, “lokal manyetik duyarlılık” olarak tarif edilmektedir (56).”
Liu, Q., Wang, L., Li, D., Zhao, J., Chen, S., & Li, J. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10596 · Cited by 5
Self-citationCattaneo, A. G., Gornati, R., Bernardini, G., Sabbioni, E., Manzo, L., & Gioacchino, M. D. (2014) · Wiley eBooks · doi:10.1002/9781118856017.ch13 · Cited by 5
Xiong, Y., Qu, Y., Min, Z., Wu, J., Zhang, S., & Xue, Z. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s351830 · Cited by 4
Shaheen, A. M., Mousa, M. H. A., Hindam, M. O., El‐Dessouki, A. M., Fahim, S. A., Hal, D. M., Ahmed, S., El‐Shiekh, R. A., & Khalifa, H. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863841 · Cited by 4
“These bio-functionalized magnetic nanoparticles have shown promising results in magnetic resonance imaging (MRI) for identifying amyloid plaques in-vivo (Wadghiri et al., 2013).”
Genome writing to dissect consequences of SVA retrotransposon disease X-Linked Dystonia ParkinsonismPreprint
Zhang, W., Zhao, Y., Prakash, P., Appleby, H. L., Barriball, K., Capponi, S., Jiang, Q., Wudzinska, A. M., Vaine, C. A., Ellis, G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.07.680816 · Cited by 5
“High-throughput ex vivo MRI of mouse heads was performed as previously described 61,62 .”
Self-citationZhao, L., Peng, T., & Wu, S. (2025) · Nanotechnology and nanomaterials. · doi:10.5772/intechopen.1008681 · Cited by 4
Surface-functionalized magnetic nanoparticles in cancer-drug delivery and diagnosis
Shah, M. R., Imran, M. A., & Ullah, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816773-1.00005-5 · Cited by 5
Evaluating the toxic oral doses of iron oxide nanoparticles in mice
Abawy, N. A., & Al-Zubaidy, M. H. I. (2023) · Al-mağallaẗ al-ʻirāqiyyaẗ li-l-ʻulūm al-bayṭariyyaẗ/Iraqi journal of veterinary sciences · doi:10.33899/ijvs.2023.138368.2796 · Cited by 4
“While the dose 150 mg/kg after 14 days of treatment causes cell swelling of hepatocytes, congestion of sinusoids, and vacuolar degeneration (Figure 6).”
BackgroundSarwal, A., Singh, G., Prasad, P., Sharma, S., & Ali, W. (2020) · Springer eBooks · doi:10.1007/978-3-030-41858-8_9 · Cited by 2
Shukla, A. K., Tiwari, A., Yadav, V. K., Yadav, V. P., Singh, M., Mishra, M. K., Pareek, A., & Jain, V. (2025) · Springer eBooks · doi:10.1007/978-981-97-9959-6_6 · Cited by 2
Image-Guided Delivery of Therapeutics to the Brain
Shah, L. K., Iyer, A. K., Talekar, M., & Amiji, M. M. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_4 · Cited by 2
“recently reported the development of USPIO-poly (ethylene) glycol (PEG)-Ab 1-42 nanoparticles to detect amyloid β plaques in Alzheimer’s disease [ 103 ].”
BackgroundImagerie multimodale TEP et IRM dans la prise en charge des démences
Jeune, F. L., & Ferré, J. (2015) · Médecine Nucléaire · doi:10.1016/j.mednuc.2015.03.192 · Cited by 2
High-Resolution Mri and Nanoparticles: the Future of Brain Imaging
Hamilton, A. M., Mallett, C. L., & Foster, P. J. (2014) · Future Neurology · doi:10.2217/fnl.13.77 · Cited by 2
Nanobiosensing disease diagnostics for in vivo applications
Sharotri, N., Ahmed, K., Sharma, D., & Agrawal, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95513-3.00028-9 · Cited by 2
Fernández, T. (2014) · UPM Digital Archive (Technical University of Madrid) · doi:10.20868/upm.thesis.32262 · Cited by 5
Sialic Acid‐Modified Nanoparticles for β‐Amyloid Studies
Kouyoumdjian, H., & Huang, X. (2015) · Wiley eBooks · doi:10.1002/9781118860212.ch12 · Cited by 1
Metadata
- Authors
- Wadghiri, Y. Z., Li, J., Wang, J., Hoang, D. M., Sun, Y., Xu, H., Tsui, W., Li, Y., Boutajangout, A., Wang, A., de Leon, M., & Wisniewski, T.
- Affiliations
- New York University (US)
- Tianjin Huanhu Hospital (CN)
- Ocean NanoTech (United States) (US)
- Corresponding author
- Wadghiri, Youssef Zaim
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-02-27
- Volume
- 8
- Issue
- 2
- Pages
- e57097
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3584149
- OpenAlex
- W2024542897
- Cited by
- 114
- References
- 54
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 11 · 2021: 2 · 2020: 8 · 2019: 11 · 2018: 11 · 2017: 10 · 2016: 9 · 2015: 12 · 2014: 15 · 2013: 3
- FWCI
- 9.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- American Health Assistance Foundation (A2008-155)
- Tianjin Science and Technology Committee
- National Institutes of Health
- National Institute on Aging (AG20245, P30AG008051, R01AG020245)
- National Cancer Institute (P30CA016087)
- National Institute of Neurological Disorders and Stroke (NS073502, R01NS073502)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Advanced MRI Techniques and Applications
- Physical Sciences › Engineering › Biomedical Engineering › Characterization and Applications of Magnetic Nanoparticles
- Keywords
- amyloid plaques, Alzheimer's disease, ultrasmall superparamagnetic iron oxide, blood-brain barrier permeability, polyethylene glycol, anti-amyloid therapy, T2 contrast, transgenic mouse model, ex vivo imaging
- MeSH terms
- Alzheimer Disease, Animals, Brain, Contrast Media, Disease Models, Animal, Magnetic Resonance Imaging, Mice, Transgenic, Amyloid beta-Peptides, Mice, Magnetite Nanoparticles, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.